Clinicopathologic significance of survivin expression in colorectal adenocarcinoma

Basic and Applied Pathology

Volumn 2, Issue 3, 2009, Pages 94-100

  Na, Woong ^a   Jang, Se Min ^a   Jun, Young Jin ^a   Song, Young Soo ^a   Jang, Ki Seok ^b   Lee, Kang Hong ^a   Lee, Kyeong Geun ^a   Han, Hong Xiu ^c   Paik, Seung Sam ^a  

^a Hanyang University   (South Korea)

^b Armed Forces Capital Hospital   (South Korea)

^c JINING MEDICAL UNIVERSITY   (China)

Author keywords

Adenocarcinoma; Colorectum; Prognosis; Survival; Survivin

Indexed keywords

EID: 77955804557     PISSN: None     EISSN: 17559294     Source Type: Journal    
DOI: 10.1111/j.1755-9294.2009.01049.x     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005, 55:74-108.
2. Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 2003, 16:376-88.
3. Paik SS, Jang KS, Song YS. Reduced expression of apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype. Ann Surg Oncol 2008, 14:3453-9.
4. Walker J, Quirke P. Prognosis and response to therapy in colorectal cancer. Eur J Cancer 2002, 38:880-6.
5. Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 2001, 8:305-10.
6. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995, 345:939-44.
7. Mcleod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer 1999, 79:191-203.
8. Nauta R, Stablein DM, Holyoke ED. Survival of patients with stage B2 colon carcinoma: the Gastrointestinal Tumor Study Group Experience. Arch Surg 1989, 124:180-2.
9. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal carcinoma. Cell 1996, 87:159-70.
10. Tan HY, Liu J, Wu SM, Luo HS. Expression of a novel apoptosis inhibitor-survivin in colorectal carcinoma. World J Gastroenterol 2005, 11:4689-92.
11. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994, 73:2013-26.
12. Meterissian SH. Apoptosis: its role in the progression of and chemotherapy for carcinoma. J Am Coll Surg 1997, 184:658-66.
13. Ambrosini G, Adida C, Altieri D. A novel anti-apoptotic gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-21.
14. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1999, 17:3247-59.
15. Li F, Ambrosini G, Chu EY. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-4.
16. Kim YY, Kim MJ, Choi KK, Hong SD, Myoung H. Survivin, possible marker and prognostic factor in oral squamous cell carcinomas. J Korean Assoc Oral Maxillofac Surg 2008, 34:71-82.
17. Adida C, Crotty PL, McGrath J. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998, 152:43-9.
18. Lee SY, Choi YJ, Kang JG, Chung EJ, Kim YT. Pathological analysis of tumor response after preoperative chemoradiation therapy for advanced rectal cancer. J Korean Soc Coloproctol 2007, 23:511-7.
19. Choi J, Hwang YK, Choi YJ. Neuronal apoptosis inhibitory protein is overexpressed in patients with unfavorable prognostic factors in breast cancer. J Korean Med Sci 2007, 22:17-23.
20. Choi HJ, Jung JH, Jung CK. Expression of survivin according to malignant progression of breast lesions. Korean J Pathol 2007, 41:238-43.
21. Seok JY, Kim SH, Lee YH, Kwon J, Kim TS. Vimentin and survivin expression rates as prognostic factors in medulloblastoma. Korean J Pathol 2007, 41:87-94.
22. Altieri DC, Marchisio C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 1999, 79:1327-33.
23. Tamm I, Wang Y, Sausville E. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspase, and anticancer drugs. Cancer Res 1998, 58:5315-20.
24. Buolamwini JK. Novel anticancer drug discovery. Curr Opin Chem Biol 1999, 3:500-9.
25. Jang JW. Anti-tumor mechanisms and regulation of survivin by selective cyclooxygenase-2 inhibitor. Korean J Hepatol 2008, 14:305-8.
26. van de Rijn M, Gilks CB. Applications of microarray to histopathology. Histopathology 2004, 44:97-108.
27. Jourdan F, Sebbagh N, Comperat E. Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 2003, 443:115-21.
28. Baldi A, Santini D, Russo P. Analysis of APAF-1 expression in human cutaneous melanoma progression. Exp Dermatol 2004, 13:93-7.
29. Reed JC, Bischoff JR. BIRinging chromosomes through cell division-and survivin' the experience. Cell 2000, 102:545-8.
30. Blanc-Brude OP, Mesri M, Wall NR. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003, 9:2683-92.
31. Abd El-Hameed A. Survivin expression in colorectal adenocarcinoma using tissue microarray. J Egypt Natl Canc Inst 2005, 17:42-50.
32. Lee YY, Yu CP, Lin CK. Expression of survivin and cortactin in colorectal adenocarcinoma: association with clinicopathologic parameters. Disease Markers 2009, 26:9-18.
33. Kawasaki H, Toyoda M, Shinohara H. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001, 91:2026-32.
34. Grossman D, McNiff JM, Fengzhi Li, Altieri DC. Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest 1999, 79:1121-6.
35. Lin LJ, Zheng CQ, Jin Y, Ma Y, Jiang WG, Ma T. Expression of survivin protein in human colorectal carcinogenesis. World J Gastroenterol 2003, 9:974-7.
36. Agui T, McConkey DJ, Tanigawa N. Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomas. Anticancer Res 2002, 22:1769-76.
37. Lam AK, Saleh S, Smith RA, Ho YH. Quantitative analysis of survivin in colorectal adenocarcinoma: increased expression and correlation with telomerase activity. Hum Pathol 2008, 39:1229-33.
38. Gerlach U, Kayser G, Walch A. Centrosome-, chromosomal-passenger- and cell-cycle-associated mRNAs are differentially regulated in the development of sporadic colorectal cancer. J Pathol 2006, 208:462-72.
39. Chen WC, Liu Q, Fu JX, Kang SY. Expression of survivin and its significance in colorectal cancer. World J Gastroenterol 2004, 10:2886-9.
40. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998, 58:5071-4.
41. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000, 46:645-50.